CR20220252A - Nuevos inhibidores de braf como rompedores de la paradoja - Google Patents

Nuevos inhibidores de braf como rompedores de la paradoja

Info

Publication number
CR20220252A
CR20220252A CR20220252A CR20220252A CR20220252A CR 20220252 A CR20220252 A CR 20220252A CR 20220252 A CR20220252 A CR 20220252A CR 20220252 A CR20220252 A CR 20220252A CR 20220252 A CR20220252 A CR 20220252A
Authority
CR
Costa Rica
Prior art keywords
braf inhibitors
new
paradox
breakers
paradox breakers
Prior art date
Application number
CR20220252A
Other languages
English (en)
Inventor
David Stephen Hewings
Juergen Wichmann
Daniela Krummenacher
Daniel Hunziker
Cosimo Dolente
Piergiorgio Francesco Tommaso Pettazzoni
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20220252A publication Critical patent/CR20220252A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Luminescent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Glass Compositions (AREA)

Abstract

La invención proporciona un compuesto novedoso que tiene la Fórmula general (I) <img src="data:image/png;base64,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 (***)
CR20220252A 2019-12-10 2020-12-08 Nuevos inhibidores de braf como rompedores de la paradoja CR20220252A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19214867 2019-12-10
PCT/EP2020/084969 WO2021116050A1 (en) 2019-12-10 2020-12-08 New braf inhibitors as paradox breakers

Publications (1)

Publication Number Publication Date
CR20220252A true CR20220252A (es) 2022-07-11

Family

ID=68848068

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220252A CR20220252A (es) 2019-12-10 2020-12-08 Nuevos inhibidores de braf como rompedores de la paradoja

Country Status (18)

Country Link
US (1) US20220298145A1 (es)
EP (1) EP4073044A1 (es)
JP (1) JP2023505300A (es)
KR (1) KR20220112777A (es)
CN (1) CN114746405B (es)
AR (1) AR120697A1 (es)
AU (1) AU2020403082A1 (es)
BR (1) BR112022010633A2 (es)
CA (1) CA3158541A1 (es)
CL (1) CL2022001492A1 (es)
CO (1) CO2022007621A2 (es)
CR (1) CR20220252A (es)
IL (1) IL292349A (es)
MX (1) MX2022006711A (es)
PE (1) PE20221027A1 (es)
TW (1) TW202136218A (es)
WO (1) WO2021116050A1 (es)
ZA (1) ZA202204092B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201608813PA (en) * 2008-03-17 2016-12-29 Ambit Biosciences Corp Quinazoline derivatives as raf kinase modulators and methods of use thereof
WO2012118492A1 (en) * 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
MX2015003535A (es) * 2012-09-19 2015-07-14 Novartis Ag Dihidro-pirrolidino-pirimidinas como inhibidoras de cinasa.
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
CR20220626A (es) * 2020-06-09 2023-01-23 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf

Also Published As

Publication number Publication date
AU2020403082A1 (en) 2022-05-12
EP4073044A1 (en) 2022-10-19
TW202136218A (zh) 2021-10-01
KR20220112777A (ko) 2022-08-11
IL292349A (en) 2022-06-01
BR112022010633A2 (pt) 2022-08-16
CA3158541A1 (en) 2021-06-17
AR120697A1 (es) 2022-03-09
US20220298145A1 (en) 2022-09-22
CN114746405B (zh) 2024-03-26
WO2021116050A1 (en) 2021-06-17
ZA202204092B (en) 2022-12-21
MX2022006711A (es) 2022-07-12
CN114746405A (zh) 2022-07-12
CL2022001492A1 (es) 2023-02-24
PE20221027A1 (es) 2022-06-16
CO2022007621A2 (es) 2022-08-30
JP2023505300A (ja) 2023-02-08

Similar Documents

Publication Publication Date Title
CR20220351A (es) Inhibidores de proteínas kras mutantes
MX2021014441A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
MX2021014443A (es) Inhibidores del dominio asociado mejorador de la transcripcion (tead) y usos de los mismos.
JOP20220008A1 (ar) مثبطات parp1
MX2021000795A (es) Compuestos heterociclicos para inhibir la actividad de shp2.
GEP20237506B (en) Pcsk9 antagonist compounds
MX2023005160A (es) Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
PH12020500655A1 (en) Compounds
MY186133A (en) Tgf-? inhibitors
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
GEP20227443B (en) Magl inhibitors
MX2018011100A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para el tratamiento de malignidades hematologicas.
MX2020006612A (es) Compuesto que funciona como inhibidor de proteína de bromodominio y composición.
GEP201706725B (en) Compounds and compositions as inhibitors of mek
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
PH12020552152A1 (en) Novel pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2
MY171768A (en) Process and composition for inhibiting the polymerization of cyclopentadiene compounds
MX2022002831A (es) Compuestos heterociclicos.
MY195889A (en) Phenyl Derivatives as Cannabinoid Receptor 2 Agonists
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
MX2020007403A (es) Compuestos de tetrahidroisoquinolina.
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
ZA202101487B (en) Novel compounds